This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
Deep Track Capital disclosed in a May 15, 2026 SEC filing that it bought 6,772,595 shares of Alumis (ALMS), valuing the estimated trade at $169.31 million based on the quarter’s average closing price. As of March 31, 2026, the stake was worth $149.20 million. Alumis shares were $22.02, up about 355% year over year.
How this was made
The 30-second read
Why it matters
The main tradable element is institutional ownership/flow signaling, which can support momentum but does not replace clinical or regulatory catalysts.
Market read
A large new institutional position in a high-momentum biotech can attract incremental attention, but the article lacks new trial/regulatory outcomes.
What to watch
No details on whether the fund’s cost basis is materially different, whether the stake is concentrated/hedged, or what specific upcoming catalysts (e.g., trial readouts) are expected.
Background
The piece summarizes a May 15, 2026 SEC filing showing Deep Track Capital’s new stake in Alumis and provides a company overview of its clinical-stage TYK2 inhibitor pipeline.
Ticker impact
Deep Track Capital disclosed a new 6,772,595-share position in Alumis worth about $169.31M, signaling fresh institutional conviction.
Near-term bias modestly positive; follow-through depends on upcoming clinical/data milestones.
The article is a Q1 2026 SEC disclosure of a large new stake and highlights strong 1Y outperformance, but it provides no new efficacy/safety or regulatory outcome.
Market effects
Large biotech fund adds to a clinical-stage name, which can modestly improve risk appetite for TYK2/autoimmune development peers.
Primarily US small/mid-cap biotech flow; limited direct cross-region impact mentioned.
No explicit global regulatory or trial geography details; relevance mainly through investor sentiment toward autoimmune biopharma.
Counterpoint
A disclosed position can reflect prior conviction rather than new information; price may already discount the move given the stock’s +355% YoY run.
Key entities
- companyAlumis
Clinical-stage biopharmaceutical developing allosteric TYK2 inhibitors (lead assets ESK-001 and A-005) for autoimmune/neuroinflammatory diseases.
- fundDeep Track Capital
Reported acquiring 6,772,595 shares of Alumis in Q1 2026, valuing the trade at about $169.31M.
